ZBB Considered Useless By NCI Staff (Privately)’ New Approach Groups Program Into Four Categories
In Brief: Upton Okays Laetrile Clinical Trials, To Seek Protocols From Clinicians For IND Request
Regulatory Agencies Get Data For Action Against One Of World’s Most Widely Used Carcinogens
Change In Method Of Counting Cancer Incidence Results In More Attributed To Work Hazards
IG Report Clears Shubik Of Conflict Of Interest Change
Trending Stories
- Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.” - Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Cancer Center at Illinois is recognized as NCI Basic Cancer Center, becoming the first new institution to earn this designation in 40 years
- Most Favored Nation drug pricing could put China on top
- NCI Director Letai wants you to know: Grant money is flowing again post-government shutdown
- Self-collection kits for HPV are among innovations adding momentum to eradication of cervical cancer
A kit for at-home unsupervised self-collection clears FDA finish line









